October 2026
Largest BioTech Public Companies in Spain
Benchmark revenue and EBITDA valuation multiples for public comps like
Grifols, Laboratorios Rovi, Almirall, Faes Farma and Pharma Mar.
 | Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products. | $11 | -13% | $6.7B | $18B | 2.2x | 10.2x | ||
| Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing. | $64 | -9% | $3.3B | $3.3B | 4.0x | 13.6x | ||
| Almirall SA is a skin-health focused pharmaceutical company based in Barcelona and the parent company of a group engaged in the purchase, manufacture, storage, marketing, and mediation in the sale of pharmaceutical specialities and products, as well as related raw materials. The Group applies science to provide medical solutions focused on skin health diseases and partners with healthcare professionals, and its activities also include cosmetics; chemical, biotechnological and diagnostic products for human, veterinary, agrochemical and food use; instruments and accessories for the chemical, pharmaceutical and clinical industry; and research on active chemical and pharmaceutical ingredients and products. | $11 | -22% | $2.5B | $2.5B | 2.0x | 9.7x | ||
| Faes Farma SA is a pharmaceutical company that specializes in the research, production, distribution, and sale of prescription and generic drugs, over-the-counter medicines, food supplements and personal care treatments, as well as raw materials for the pharmaceutical use. The company develops new drugs for the treatment of allergy, venous insufficiency, and irritable bowel syndrome. It also provides animal nutrition products. Faes Farma exports its products to more than 60 countries and has operations in Spain, Portugal, Chile, and Mexico, among others. | $6 | +7% | $1.7B | $2B | 2.9x | 15.1x | ||
| Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business. | $77 | -10% | $1.3B | $1.2B | 4.8x | 15.8x | ||
| Natac Natural Ingredients SA is engaged in producing sustainable natural ingredients from botanicals and fish. The company researches, develops, produces, and markets natural ingredients derived from plant extracts. The group has two operating segments: Vegetable extracts, and Omega-3, of which it derives maximum revenue from Vegetable Extracts. | $1 | -34% | $271M | $364M | 6.8x | 22.7x | ||
| Laboratorio Reig Jofre SA is a healthcare and pharmaceutical developing company. The company focuses on the development of technological-specialization products (antibiotics and injectable products); therapeutic-specialization products in the areas of dermatology, gynecology and respiratory; and consumer healthcare products. It has a broad portfolio of products that the company divides into three categories: products from specialized technology such as antibiotics, injectable, and freeze-dried products. | $3 | -13% | $240M | $360M | 1.0x | 11.7x | ||
| Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases. | $3 | -30% | $234M | $224M | - | (36.0x) | ||
| Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology. | $3 | -20% | $223M | $341M | 2.2x | (28.9x) | ||
| Vytrus Biotech is a Barcelona, ESP-based operating company active in Biopharmaceuticals. Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni. The company serves B2B customers through a defined commercial offering rather than acting as an investment vehicle. Its recorded revenue model is Product sales, describing how customers pay for the operating product or service. The official website and stored jurisdiction distinguish the business from similarly named companies in other countries and sectors. ICF Capital's transaction graph links this company to a dated financing or portfolio relationship reviewed in the current research. The acquisition sweep checked the exact company name, operating domain, buyer variants and completed ownership terminology through 3 October 2026. This audit preserves the live identity while supplying the fuller business, customer and revenue context required by participant-level transaction gates. | $18 | +133% | $138M | $136M | 14.6x | 29.7x | ||
| Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services. | $2 | -19% | $58M | $61M | 3.8x | (58.0x) | ||
| Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include a GMP manufacturer for EU animal and human health industries, a manufacturer specializing in sterile and lyophilized dosage forms, and a source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol. The company operates in two segment Animal Health and Human Health. | $6 | +14% | $48M | $83M | 1.0x | 6.8x | ||
| Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others. | $0 | -41% | $18M | $21M | 6.2x | 34.7x | ||
| Median | $6 | -13% | $240M | $360M | 3.4x | 11.7x |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Recent Insights
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.